Few people have missed the fact that there is a harsh climate in the capital market for biotech companies right now. One company that has so far survived in this frosty environment is Cline Scientific, which this summer raised approximately 6.1 MSEK for the continued work of driving the main project StemCART towards clinical studies. BioStock spoke to CEO Patrik Sundh to get his thoughts on the state of the market, the financing and the value-adding milestones that the company is working towards.
Read the full article at biostock.se (https://www.biostock.se/en/):
https://www.biostock.se/en/2023/12/clines-ceo-gotten-a-long-way-with-small-means/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se